Medicare AdvantagePrior AuthMedium impact
DPP-IV, SGLT2 Combination Products (Revised)
Humana·Endocrinology, Family Medicine, Internal Medicine +1 more·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for DPP-IV/SGLT2 combination diabetes medications (Steglujan, Qtern, and generic dapagliflozin-saxagliptin) effective January 1, 2026. Patients must have tried individual DPP-4 or SGLT2 inhibitors first, or have contraindications to them.
Action Required
By January 1, 2026: Billing team must update prior authorization system to require preapproval for Steglujan, Qtern, and dapagliflozin-saxagliptin tablets for Humana Medicare Advantage patients. Providers must document previous treatment with or contraindications to individual DPP-4 inhibitors (sitagliptin, linagliptin) or SGLT2 inhibitors (empagliflozin, dapagliflozin) before prescribing combination products. Update EMR templates to include diabetes medication history documentation.